SYMPOSIUM: TAKE HOME NALOXONE – Recent achievements and new pathways towards universal access

Authors: Caroline Shalom[1,2], Angela Matheson[3], Tegan Nuckey[4], Robyn Greaves[5], Grace Oh[6], Suzanne Nielsen[7,8], Nick Scott[7], Tom Tidhar[7], Maria Del Mar Quirga[7,9], Simon Lenton[10], Paul Dietze[7,8,10]

[1]The University Of Queensland, Indooroopilly, Australia, [2]National Drug and Alcohol Research Centre, UNSW, Sydney, Australia, [3]Centre for Alcohol & Other Drugs, NSW Ministry of Health, Sydney, Australia, [4]QuIHN, Gold Coast, Australia, [5]Mental Health, Alcohol and Drug Directorate, Department of Health, Hobart, Australia, [6]Mental Health Commission, Perth, Western Australia, [7]Australia, Behaviours and Health Risks, Burnet Institute, [8]Monash Addiction Research Centre, Melbourne, Australia, [9]Melbourne Data Analytics Platform, University of Melbourne, Melbourne, Victoria, [10]National Drug Research Institute, Curtin University, Perth, Australia,

Chair: Caroline Salom [1,2]
[1] *Institute for Social Science Research, The University of Queensland, Brisbane, Australia*
[2] *National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia*

Chair's email: *c.salom@uq.edu.au*

Aim: *To consider successful aspects of current take-home naloxone programs in Australia, looking forward to a nationally coherent program.*

PRESENTATION 1: Scaling up an innovative take home naloxone model to public and non-government services across NSW

Presenting Authors: Angela Matheson

Presenter's email: Angela.Matheson@health.nsw.gov.au

Introduction: Opioid overdose deaths have been increasing across Australia. NSW Health has responded by scaling up an innovative, recently piloted and evaluated take home naloxone model across public and non-government health services.

Approach: Since 2019, NSW Health has implemented a Take Home Naloxone Program through alcohol and other drugs services across NSW. Initially focusing on public health services, the Program is now also being implemented in non-government organisations.

Program implementation has required an authorising environment utilising regulatory and policy innovations; extensive investment in staff capacity; and support for organisational change. For participating non-government services, NSW Health also established a mechanism for supplying naloxone medicines to them. Ongoing communication with health workers, target populations and the broader community is being undertaken to build awareness of, and demand for, naloxone among people most likely to experience or witness an opioid overdose.

Results: As at June 2021, 94 public and justice health services across NSW now provide take home naloxone interventions to eligible people. 44 non-government organisations have been trained and legally enabled to supply naloxone to their clients.

Discussions and Conclusions: A diverse workforce of allied health, drug and alcohol and consumer workers is demonstrably well-placed and skilled to provide take home naloxone interventions to eligible clients to support them to prevent and respond to opioid overdoses. A range of regulatory, scope of practice and organisational change challenges were encountered. The solutions developed to address these in the NSW context will be explored, to help inform program development in other jurisdictions.

Disclosure of Interest Statement: *NSW is a participating site in the Australian Government PBS-subsidised naloxone pilot. Since March 2020, the pilot has subsidised most of the cost of naloxone supplied by public health and non-government services in NSW. NSW Health does not receive direct funding as a pilot participant.*

PRESENTATION 2: Take Home Naloxone Supply in Queensland

Presenting Authors: Tegan Nuckey

Presenter's email: TNuckey@quihn.org

Introduction issues: Many barriers in Queensland impede access to naloxone:

- No funding within Queensland Health to drive initiatives.
- No QLD funding for other services to supply.
- No pathway regarding approval for supply.
- Exclusion from the PBS-Subsidised Naloxone Pilot.
- Pharmacies do not have stock readily available.
- Cost of purchasing without a script.
- Resistance from GPs, Emergency Departments, and Opioid Treatment providers.
- Lack of education/awareness across sectors.

QuIHN's goal is to reduce harms associated with drug use; expanding naloxone access is an important part of this response.

Approach: To address gaps and reduce barriers to accessing naloxone in QLD we developed a THN program, adapted from WA's SASA naloxone project 2018-2020. This aims to increase naloxone availability for Gold Coast, Sunshine Coast, Townsville and Brisbane regions. QuIHN applied for Approval to obtain, possess, and use scheduled substances for non-therapeutic purposes. In March 2020 a section 18(1) Approval was received.

The program operates from QuIHN's Needle and Syringe Programs. Approval allows non-medical NSP workers/volunteers to train and supply free naloxone to people at risk of witnessing/experiencing opioid overdose.

Key Findings: From July 2020 to April 2021 QuIHN has supplied 585 naloxone doses. 41 people have returned for resupply, with no reports of adverse effects from naloxone administration.

Discussions and Conclusions: Australia needs a range of responses to address climbing rates of opioid overdose deaths.

Implications for Practice or Policy:These include ready access to naloxone, increased availability of OTP and increased attention to overdose risks in people receiving prescription

opioids. States are gradually introducing real-time prescription monitoring of targeted medications to promote supply reduction. QuIHN's THN initiative is a valuable addition to these responses, targeting harm reduction for those at high risk of overdose. Increasing coverage across all NSPs is a logical next step once regulatory and funding issues are addressed.

PRESENTATION 3: TAKE HOME NALOXONE PILOT IN TASMANIA

Presenting Authors: Robyn Greaves

Presenters email: robyn.greaves@health.tas.gov.au,

Issues: Naloxone has always been available in Tasmania - either on prescription from a doctor, subsidised by the Pharmaceutical Benefits Scheme (PBS), or supplied from a community pharmacy through a PBS prescription, or over the counter from a pharmacist (unsubsidised). However, until recently, this availability was not widely known. The cost of naloxone, even under the PBS, is prohibitive for most people.

As part of its response to COVID-19, the Tasmanian Government funded a trial of free take-home naloxone through Needle and Syringe Program (NSP) outlets across Tasmania. The trial took place from 1 July 2020 – end February 2021, to coincide with the Commonwealth-funded national pilot (taking place in NSW, SA and WA), which has since been extended to 30 June 2022.

Approach: Amendments to the Tasmanian *Poisons Regulations 2018* enable naloxone to be supplied to a person deemed at risk of opioid overdose by a certified NSP worker at a permitted premises.
The Tasmanian Department of Health developed documentation and worked closely with NSP workers to establish the trial. Training was provided through the Penington Institute. Naloxone was provided in the form of the intranasal spray, Nxyoid.

Key Findings: 380 units of Nyxoid were ordered and distributed to NSPs across the course of the trial. 254 units of Nxyoid were supplied to clients. There were 13 reported overdose reversals.

Discussion and Conclusions: The Tasmanian Government has agreed to continue the free take-home naloxone program through NSPs.

Implications for Practice or Policy: Investigate the possibility of expanding the program in Tasmania, dependent upon the national approach.

PRESENTATION 4: First on scene, last on scene - supporting the in between

Presenting Authors: Grace Oh

Presenters email: grace.oh@mhc.wa.gov.au

Introduction: Western Australia has a significant take-home naloxone program and has pioneered multiple approaches for expanding take-home naloxone access resulting in 230 access points for Naloxone for community access. However, gaps remain in providing

access to other first responders and for those at higher risk such as people who refuse ambulance transport once they have been revived.

Approach: The Mental Health Commission has been working collaboratively with WA Police and St Johns Ambulance Association to include naloxone nasal spray in frontline worker First Aid kits.

Findings: The WA Police Naloxone Pilot will roll out on July 1,2021 and SJAA 's take home naloxone program will roll out on October 1,2021. As background, the Mental Health Commission has provided training to 280 police officers across 5 WA jurisdictions. Police are being trained to recognise and respond to opioid overdose and administer Naloxone. Paramedics are being trained to deliver take-home naloxone training and provide naloxone to family, friends, witnesses and the patient in settings where they attend people who have had an overdose but refuse transport. Feedback from training and outcomes are being collated on these programs, the first of their type in Australia.

Discussion and Conclusions: Findings from these innovative programs in WA will inform the development of programs in other jurisdictions to help close the remaining gaps in take-home naloxone distribution and ensure more widespread access to this life-saving drug.

PRESENTATION 5: The impact of distributing naloxone to people who are prescribed opioids to prevent opioid-related deaths: findings from a modelling and cost-effectiveness study.

Presenting Authors: Suzanne Nielsen

Presenters email: suzanne.nielsen@monash.edu

Introduction: Most research on naloxone supply has focused on people who inject heroin. In Australia, most opioid-related mortality involves prescription opioids, yet few studies have examined the potential impact of upscaling naloxone supply to people who are prescribed opioids.

Methods: We used a decision-tree model to estimate the possible deaths averted, costs (ambulance and naloxone distribution), and cost-per-life-saved for different scenarios of naloxone scale-up among people prescribed opioids in Australia. Four scenarios were compared to a baseline (no naloxone supply): naloxone scale-up between 2020-2030 to reach 30% or 90% coverage by 2030, among people prescribed either >=100mg or >=50mg of Oral Morphine Equivalents (OME).

Results: Without naloxone, there would be an estimated 7,478 [Uncertainty Interval (UI) 6,868–8,275] prescription opioid overdose deaths between 2020-2030, resulting in AUD51.9 million [49.4–56.0] in ambulance costs. If naloxone was scaled up to 90% of people prescribed >=50mg OME, an estimated 657 [UI 245–1,489] deaths could be averted between 2020-2030 (a 20% reduction in 2030 compared to the no naloxone scenario), with a cost of AUD43,600 (20,800–110,500) per life saved. If naloxone was restricted to those prescribed >=100mg OME, an estimated 130 (UI 44–289) deaths would be averted if scaled up to 30%, or 390 (UI 131–866) deaths averted if scaled up to 90%, with the cost-per-life-saved for both scenarios AUD38,200 (UI 12,400–97,400).

Discussions and Conclusions: Scaling up take-home naloxone to reach 90% of people prescribed daily doses of 50mg OME is a cost-effective intervention that would save lives.

Implications for Practice or Policy: Although our study suggests that take-home naloxone represents a cost-effective approach to opioid overdose among people who use prescription opioids, scaling up take-home naloxone to reach this population has proven difficult. If key implementation barriers were to be addressed, scaling up naloxone could prevent considerable mortality.

Disclosure of Interest Statement: This work was supported by funding from the Australian Government, Department of Health. SN and PD are recipients of National Health and Medical Research Council (NHMRC) Research Fellowship (APP1163961 and APP1136908). SN has received untied educational grants from Seqirus to investigate prescription opioid related harms, and is a named investigator on a research grant from Indivior on a long-acting injectable buprenorphine implementation study. PD received investigator driven funding from Gilead Sciences and an untied educational grant from Indivior. SN and PD participated as unpaid members of an advisory board meeting for Mundipharma discussing intranasal naloxone.

Discussion Section: Professor Dietze will draw on experience of working with the National Naloxone Reference Group to synthesise the findings and highlight the major gaps in take home naloxone delivery across Australia. The focus for audience members will be on what can be done now to expand and extend programs and how initiatives such as the Commonwealth PBS pilot will be able to be leveraged to increase take-home naloxone coverage in Australia.

Discussant: Paul Dietze [1,2]
[1] Burnet Institute, Melbourne, Australia
[2] National Drug Research Institute, Curtin University, Perth, Australia

Discussant's email: *paul.dietze@burnet.edu.au*

Disclosure of Interest Statement: *PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant related to the introduction of a Buprenorphine-Naloxone formulation. PD has served as an unpaid member of an advisory board for an intranasal naloxone product.*